TXMD News and Press, TherapeuticsMD Inc. From 05/20/22

3 Hot Biotech Penny Stocks to Add to Your Watchlist With the Market Down Recently, biotech penny stocks have seen heightened bullish sentiment. Today, the emphasis on biotech stocks comes as the Monkeypox virus is seeing a resurgence in certain areas around the world. Today, the WHO con...

Gainers: Leju Holdings Limited (LEJU) +47%. Redbox Entertainment (RDBX) +33%. SIGA Technologies (SIGA) +26%. Getnet (GET) +25%. Allarity (ALLR) +23%. NanoViricides (NNVC) +22%. Processa Pharmaceuticals (PCSA) +22%. TherapeuticsMD (TXMD) +17%. PyroGenesis Canada (PYR) +17%. Evofem Biosciences ...

The U.S. FDA had granted approval to a supplemental New Drug Application from TherapeuticsMD (NASDAQ:TXMD) for its Annovera birth control ring. Shares are up 25% in Friday morning trading. The company said that the approval should lead to fewer batch rejections and increase future p...

- ANNOVERA is the only FDA-approved procedure-free, long-lasting, reversible birth control - - With this approval, the Company expects a significant reduction in its manufacturing batch rejections and an increase in future product supply and will enable the Company to better meet sh...

Gainers: Scholar Rock (SRRK) +26%. Phathom Pharmaceuticals (PHAT) +12%. 4d Pharma  (LBPS) +10%. Ocular Therapeutix (OCUL) +9%. Magenta Therapeutics (MGTA) +8%. Losers: PolarityTE (PTE) -34%. Tonix Pharmaceuticals (TNXP) -22%. Albireo Pharma (ALBO) ...

Image source: The Motley Fool. TherapeuticsMD, Inc. (NASDAQ: TXMD) Q1 2022 Earnings Call May 16, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: TherapeuticsMD, Inc. (TXMD) Q1 2022 Earnings Call Transcript

TherapeuticsMD (NASDAQ:TXMD) saw its Q1 2022 net loss widen 24% to $49M (-$5.69 basic and diluted share) compared to the prior-year period weighed down by a $8.4M loss on extinguishment of debt The net loss was a miss while revenue of ~$19.3M, around a 3% year-over-year-decline, was a beat. T...

Therapeutics MD press release (NASDAQ:TXMD): Q1 GAAP EPS of -$5.69 misses by $1.69. Revenue of $19.34M (-2.7% Y/Y) beats by $1.39M. For further details see: Therapeutics MD GAAP EPS of -$5.69 misses by $1.69, revenue of $19.34M beats by $1.39M

- Quarterly total net product revenue of $19.3 million - - ANNOVERA® TRx of 8,014, an increase of 27% over Q1 2021 - - Announced and completed vitaCare divestiture in five weeks - - Conference call scheduled for 4:30 p.m. ET today - TherapeuticsMD, Inc. (“TXMD&...

-Executive Management to Host Conference Call on May 16, 2022, at 4:30 p.m. ET- TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that it will report its first quar...